Format

Send to

Choose Destination
Curr Hematol Malig Rep. 2019 Nov 7. doi: 10.1007/s11899-019-00549-1. [Epub ahead of print]

The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Shanmuganathan N1,2,3,4,5, Branford S6,7,8,9,10.

Author information

1
Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia. naranie.shanmuganathan@sa.gov.au.
2
Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia. naranie.shanmuganathan@sa.gov.au.
3
School of Medicine, University of Adelaide, Adelaide, Australia. naranie.shanmuganathan@sa.gov.au.
4
Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia. naranie.shanmuganathan@sa.gov.au.
5
School of Health Sciences, University of South Australia, Adelaide, Australia. naranie.shanmuganathan@sa.gov.au.
6
Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia.
7
Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.
8
School of Medicine, University of Adelaide, Adelaide, Australia.
9
School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.
10
School of Biological Sciences, University of Adelaide, Adelaide, Australia.

Abstract

PURPOSE OF REVIEW:

Identification of the BCR-ABL1 fusion oncogene in patients diagnosed with chronic myeloid leukemia (CML) led to the development of targeted therapy responsible for the dramatic survival benefits observed in the past two decades. However, despite these revolutionary findings, there remains marked disparity in patient outcomes. Why do some patients present de novo while others evolve to the more aggressive stages of CML? Why can select patients successfully discontinue therapy as part of a treatment-free remission attempt whereas others fail to meet specific molecular milestones?

RECENT FINDINGS:

BCR-ABL1 kinase mutations are only identified in approximately 50% of patients with poor responses and disease progression, suggesting the presence of alternative resistance mechanisms. Numerous institutions have identified the presence of additional genomic events in addition to BCR-ABL1 with the increasing availability of next-generation sequencing. We explore the potential pathways and events that may cooperate with BCR-ABL1 to answer these questions but also challenge the fundamental tenet that BCR-ABL1 is always the sole event initiating CML.

KEYWORDS:

Disease progression; Mutations; Next-generation sequencing; Resistance

PMID:
31696382
DOI:
10.1007/s11899-019-00549-1

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center